About Abaxis (NASDAQ:ABAX)
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Industry, Sector and Symbol
Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio64.54
Forward P/E Ratio56.26
Sales & Book Value
Annual Sales$244.70 million
Price / Sales7.78
Cash Flow$1.7142 per share
Price / Cash48.57
Book Value$12.81 per share
Price / Book6.50
EPS (Most Recent Fiscal Year)$1.29
Net Income$27.17 million
Return on Equity10.65%
Return on Assets9.12%
Abaxis (NASDAQ:ABAX) Frequently Asked Questions
What is Abaxis' stock symbol?
Abaxis trades on the NASDAQ under the ticker symbol "ABAX."
How often does Abaxis pay dividends? What is the dividend yield for Abaxis?
Abaxis declared a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, June 1st will be paid a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 31st. This is a boost from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.
How will Abaxis' stock buyback program work?
Abaxis announced that its board has initiated a share repurchase plan on Wednesday, October 25th 2017, which allows the company to repurchase $21,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.
How were Abaxis' earnings last quarter?
Abaxis Inc (NASDAQ:ABAX) announced its quarterly earnings results on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.10. The medical research company earned $67.90 million during the quarter, compared to the consensus estimate of $66.02 million. Abaxis had a net margin of 11.11% and a return on equity of 10.65%. The business's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 earnings per share. View Abaxis' Earnings History.
When is Abaxis' next earnings date?
What price target have analysts set for ABAX?
9 brokers have issued 12-month target prices for Abaxis' stock. Their forecasts range from $48.00 to $65.00. On average, they expect Abaxis' stock price to reach $58.3333 in the next year. View Analyst Ratings for Abaxis.
Who are some of Abaxis' key competitors?
Some companies that are related to Abaxis include Cubic (CUB), MTS Systems (MTSC), Nanometrics (NANO), Faro Technologies (FARO), Oxford Instruments (OXINF), Geospace Technologies (GEOS), Cemtrex (CETX), Image Sensing Systems (ISNS), Midwest Energy Emissions (MEEC), Mikros Systems (MKRS), Sierra Monitor (SRMC), Mechanical Technology (MKTY) and Visualant (VSUL).
Who are Abaxis' key executives?
Abaxis' management team includes the folowing people:
- Mr. Clinton H. Severson, Chairman and Chief Exec. Officer (Age 70)
- Mr. Donald P. Wood, Pres & COO (Age 66)
- Mr. Ross Taylor Jr., CFO, Principal Accounting Officer, VP of Fin. & Sec. (Age 55)
- Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
- Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)
Has Abaxis been receiving favorable news coverage?
News coverage about ABAX stock has been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abaxis earned a media sentiment score of 0.45 on Accern's scale. They also assigned headlines about the medical research company an impact score of 43.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Abaxis' major shareholders?
Abaxis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (16.82%), BlackRock Inc. (13.92%), Dimensional Fund Advisors LP (3.13%), Wells Fargo & Company MN (2.96%), Royal Bank of Canada (1.81%) and Copeland Capital Management LLC (1.45%). Company insiders that own Abaxis stock include Achim Henkel, Clinton Severson, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey, Prithipal Singh and Richard Bastiani. View Institutional Ownership Trends for Abaxis.
Which major investors are selling Abaxis stock?
ABAX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Echo Street Capital Management LLC, Royal Bank of Canada, Tiverton Asset Management LLC, Spark Investment Management LLC, Glen Harbor Capital Management LLC, Rhumbline Advisers and JPMorgan Chase & Co.. Company insiders that have sold Abaxis company stock in the last year include Achim Henkel, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey and Prithipal Singh. View Insider Buying and Selling for Abaxis.
Which major investors are buying Abaxis stock?
ABAX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Rockefeller Capital Management L.P., Kayne Anderson Rudnick Investment Management LLC, Pier Capital LLC, WINTON GROUP Ltd, Federated Investors Inc. PA, Wells Fargo & Company MN and Millennium Management LLC. View Insider Buying and Selling for Abaxis.
How do I buy shares of Abaxis?
Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abaxis' stock price today?
One share of ABAX stock can currently be purchased for approximately $83.26.
How big of a company is Abaxis?
Abaxis has a market capitalization of $1.90 billion and generates $244.70 million in revenue each year. The medical research company earns $27.17 million in net income (profit) each year or $1.29 on an earnings per share basis. Abaxis employs 656 workers across the globe.
How can I contact Abaxis?
Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]
MarketBeat Community Rating for Abaxis (ABAX)MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.